Literature DB >> 10358047

The binding interface between an E2 (UBC9) and a ubiquitin homologue (UBL1).

Q Liu1, C Jin, X Liao, Z Shen, D J Chen, Y Chen.   

Abstract

Human UBC9 is a member of the E2 (ubiquitin conjugation enzyme) family of proteins. Instead of conjugating to ubiquitin, it conjugates with a ubiquitin homologue UBL1 (also known as SUMO-1, GMP1, SMTP3, PIC1, and sentrin). UBC9 has been shown to be involved in cell cycle regulation, DNA repair, and p53-dependent processes. The binding interfaces of the UBC9 and UBL1 complex have been determined by chemical shift perturbation using nuclear magnetic resonance spectroscopy. The binding site of UBL1 resides on the ubiquitin domain, and the binding site of UBC9 is located on a structurally conserved region of E2. Because the UBC9-UBL1 system shares many similarities with the ubiquitin system in structures and in conjugation with each other and with target proteins, the observed binding interfaces may be conserved in E2-ubiquitin interactions in general.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10358047     DOI: 10.1074/jbc.274.24.16979

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Solution structure of a yeast ubiquitin-like protein Smt3: the role of structurally less defined sequences in protein-protein recognitions.

Authors:  Wanyun Sheng; Xiubei Liao
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

2.  EBNA3C coactivation with EBNA2 requires a SUMO homology domain.

Authors:  Adam Rosendorff; Diego Illanes; Gregory David; Jeffrey Lin; Elliott Kieff; Eric Johannsen
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

3.  A unique E1-E2 interaction required for optimal conjugation of the ubiquitin-like protein NEDD8.

Authors:  Danny T Huang; David W Miller; Rose Mathew; Robert Cassell; James M Holton; Martine F Roussel; Brenda A Schulman
Journal:  Nat Struct Mol Biol       Date:  2004-09-07       Impact factor: 15.369

4.  Small ubiquitin-like modifier (SUMO) modification of E1 Cys domain inhibits E1 Cys domain enzymatic activity.

Authors:  Khue Truong; Terry D Lee; Yuan Chen
Journal:  J Biol Chem       Date:  2012-03-08       Impact factor: 5.157

5.  Mechanism of E1-E2 interaction for the inhibition of Ubl adenylation.

Authors:  Jianghai Wang; Sheng Cai; Yuan Chen
Journal:  J Biol Chem       Date:  2010-08-03       Impact factor: 5.157

6.  Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1.

Authors:  Luisa Maria Lois; Christopher D Lima
Journal:  EMBO J       Date:  2005-01-20       Impact factor: 11.598

7.  A small conserved surface in SUMO is the critical structural determinant of its transcriptional inhibitory properties.

Authors:  Sergey Chupreta; Sam Holmstrom; Lalitha Subramanian; Jorge A Iñiguez-Lluhí
Journal:  Mol Cell Biol       Date:  2005-05       Impact factor: 4.272

8.  Vaccinations with recombinant variants of Aspergillus fumigatus allergen Asp f 3 protect mice against invasive aspergillosis.

Authors:  James I Ito; Joseph M Lyons; Teresa B Hong; Daniel Tamae; Yi-Kuang Liu; Sharon P Wilczynski; Markus Kalkum
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

9.  Structure of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway.

Authors:  David M Duda; Robert C A M van Waardenburg; Laura A Borg; Sierra McGarity; Amanda Nourse; M Brett Waddell; Mary-Ann Bjornsti; Brenda A Schulman
Journal:  J Mol Biol       Date:  2007-04-10       Impact factor: 5.469

10.  Identification of a SUMO-binding motif that recognizes SUMO-modified proteins.

Authors:  Jing Song; Linda K Durrin; Thomas A Wilkinson; Theodore G Krontiris; Yuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.